GlaxoSmithKline Pharmaceuticals Limited has announced a key leadership appointment, naming Mr. Vinay Subramanian as Commercial Head – Oncology to its leadership team. The appointment, effective 20th April 2026, was disclosed to stock exchanges in compliance with Regulation 30 of SEBI Listing Regulations.

Leadership Appointment Details

The company informed BSE Limited and National Stock Exchange of India Limited about the appointment through an official communication dated 21st April 2026. Subramanian will be based out of Mumbai and will be part of the senior management personnel of the company.

Professional Background and Experience

Vinay Subramanian brings extensive experience spanning over 24 years in the pharmaceuticals, life science, healthcare devices, and medical technology sectors. His appointment strengthens GSK's oncology division leadership with proven industry expertise.

Prior to joining GSK, Subramanian served as the India Enabling leader - Enterprise & Neighboring Countries at Roche Products India Pvt Ltd. In this role, he was responsible for managing the immunotherapy portfolio and was an integral part of their leadership team.

Previous Leadership Roles

Subramanian's career includes significant leadership positions across major healthcare organizations:

Educational Qualifications

Subramanian holds comprehensive educational credentials that complement his extensive industry experience:

Regulatory Compliance

The appointment disclosure was made in accordance with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that there are no relationships between directors that require disclosure under the regulatory framework.

The communication was signed by Ajay Nadkarni, Vice President – Administration, Real Estate & Company Secretary, ensuring proper corporate governance protocols were followed in the announcement.

GlaxoSmithKline Pharmaceuticals Limited has announced the authorization of four senior executives to determine the materiality of events or transactions for regulatory disclosures to stock exchanges. The disclosure was made on 21st April 2026 in compliance with Regulation 30(5) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Authorized Personnel for Material Event Assessment

The Board of Directors has jointly authorized four key personnel to assess the materiality of events requiring disclosure to BSE and NSE. This authorization ensures streamlined decision-making for regulatory compliance and timely disclosure of material information to investors.

Regulatory Compliance Framework

This authorization falls under Regulation 30(5) of SEBI's Listing Obligation and Disclosure Requirements Regulations, 2015, which mandates listed companies to establish clear protocols for determining material events. The regulation requires companies to designate authorized personnel who can collectively assess whether specific events or transactions meet the materiality threshold for public disclosure.

Corporate Governance Structure

The authorized team represents key functional areas within the organization, combining operational leadership, financial oversight, legal compliance, and corporate secretarial functions. This cross-functional approach ensures comprehensive evaluation of events from multiple business perspectives before making disclosure decisions.

The disclosure was formally communicated to both BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai, and The National Stock Exchange of India Limited at Exchange Plaza, Bandra-Kurla Complex, Mumbai. Company Secretary Ajay Nadkarni, who also serves as Vice President – Administration and Real Estate, signed the communication on behalf of the company.